• Chiydem Ismailova National Centre of Infectious and Parasitic Diseases
  • Vlilana Yontcheva National Centre of Infectious and Parasitic Diseases
  • Tencho Tenev National Centre of Infectious and Parasitic Diseases
  • Elitsa Golkocheva-Markova National Centre of Infectious and Parasitic Diseases


Hepatitis C virus, recombinant immunoblot assay, antibodies


Background: Hepatitis C virus (HCV) is an RNA virus causing acute or chronic infection and affecting more than 2% of population worldwide. The firstline tests for diagnosis of HCV infection are 3rd or 4th generation enzyme immunoassays - ELISA and CIA. They indicate the presence of antibodies against HCV in serum. These tests are characterized by high sensitivity and specificity, but they cannot distinguish past, acute or chronic infection, and sometimes produce false positive results. Confirmatory tests, such as recombinant immunoblot-line immune assay (LIA), and quantitative PCR, are used to validate the positive antibody response. The recombinant immunoblot assay can be used to determine the specificity of antibody to HCV. The aim of the present study is to determine the correlation between the anti-HCV response in confirmatory immunoblot assay and the HCV viral load, measured by PCR.

Materials and methods: Twenty-nine anti-HCV positive sera were included in the study. Third generation ELISA assay was used for anti-HCV screening of the samples and for detection of anti-HCV antibodies against specific HCV proteins. Third generation line immunoassay INNO-LIA HCV Score, based on the principle of an enzyme immunoassay, was used as a confirmatory test. The HCV viral load was measured by quantitative PCR method – Abbott Real Time HCV (Abbott Molecular Inc., USA) with linear sensitivity range from 1.08 Log 10 IU/ml (12 [IU/ml]) to 8.00 Log 10 IU/ml (100 000 000 [IU/ml]).

Results: HCV RNA was quantified in all studied samples. Ten of 29 serum samples (34%, Group I) were HCV RNA negative. The rest of the samples were HCV RNA positive as follows: 3 serums were with minimal viral load from < 12 to 10 000 IU/ml (10%, Group II); 3 serum samples –between 10 000 and 100 000 IU/ml (10%, Group III); 10 serum samples – between 100 000 and 1 000 000 IU/ml (34%, Group IV) and in 3 serum samples HCV RNA concentration was over 1 000 000 IU/ml (10%, Group V).

Conclusion: HCV screening strategies involving anti-HCV detection by ELISA combined with recombinant immunoblot assay can be the method of choice in laboratories with limited equipment and finances.

Author Biographies

Chiydem Ismailova, National Centre of Infectious and Parasitic Diseases

NRL “Hepatitis viruses”

Vlilana Yontcheva, National Centre of Infectious and Parasitic Diseases

NRL “Hepatitis viruses”

Tencho Tenev, National Centre of Infectious and Parasitic Diseases

Head of NRL “Hepatitis viruses”

Elitsa Golkocheva-Markova, National Centre of Infectious and Parasitic Diseases

NRL “Hepatitis viruses”


WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO

Bruno S, Facciotto C. The natural course of HCV infection and the need for treatment. Annals Hepatol., 2008; 7 (2): 114-119

Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012 Jul;55 Suppl 1:S43-8. doi: 10.1093/cid/cis368. PMID: 22715213

Kodani M, Martin M, de Castro VL, Drobeniuc J, Kamili S. An Automated Immunoblot Method for Detection of IgG Antibodies to Hepatitis C Virus: a Potential Supplemental Antibody Confirmatory Assay. J Clin Microbiol. 2019;57(3):e01567-18. Published 2019 Feb 27. doi:10.1128/JCM.01567-18

Warkad SD, Song KS, Pal D, Nimse SB. Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies. Sensors (Basel). 2019;19(19):4257. Published 2019 Sep 30. doi:10.3390/s19194257

Ashfaq, U.A., Javed, T., Rehman, al.An overview of HCV molecular biology, replication and immune responses.VirolJ8,161(2011).

Sperle I, Nielsen S, Gassowski M et al. Prevalence of hepatitis C in the adult population of Bulgaria: a pilot study. BMC Res Notes 13, 326 (2020).

Vladimirova N, Kamenov G, Stoitsova S, Minkova A, Parmakova K, Acute infectious diseases in Bulgaria in 2019 (Main epidemiological indicators). Epidemiology analysis 2019, NCIPD

Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000 May;6(5):578-82. doi: 10.1038/75063. PMID: 10802716.

Santos, Vanessa Costa dos, Schinoni, Maria Isabel, Oliveira, Isabela Silva de, Atta, Maria Luiza Sousa, & Atta, Ajax Mercês. (2019). IgG1 and IgG4 antibodies against Core and NS3 antigens of hepatitis C virus. Revista da Sociedade Brasileira de Medicina Tropical, 52, e20180491. Epub March 07, 2019.

Bian Y, Zhao S, Zhu S, Zeng J, Li T, Fu Y et al. (2013) Significance of Monoclonal Antibodies against the Conserved Epitopes within Non-Structural Protein 3 Helicase of Hepatitis C Virus. PLoS ONE 8(7): e70214.

Strasak AM, Kim AY, Lauer GM, et al. Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil. BMC Infect Dis. 2011; 11: 15. doi:10.1186/1471-2334-11-15

De Marco L, Manzini P, Trevisan M, Gillio-Tos A, Danielle F, Balloco C, et al. (2012) Prevalence and Follow-Up of Occult HCV Infection in an Italian Population Free of Clinically Detectable Infectious Liver Disease. PLoS ONE 7(8): e43541.

Grebely J, Prins M, Hellard M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12(5):408-414. doi:10.1016/S1473-3099(12)70010-5

Rando-Segura A, Buti M, Quer J, López-Martínez R, Rodríguez-Frías F. Viral Load Measurements in Individuals with Hepatitis C Virus Infection: on the European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C 2018. J Clin Microbiol. 2019;58(1):e01379-19. Published 2019 Dec 23. doi:10.1128/JCM.01379-19

Pereira, Felicidade Mota, Zarife, Maria Alice Sant'ana, Reis, Eliana Almeida Gomes, & G. Reis, Mitermayer. (2014). Indeterminate RIBA results were associated with the absence of hepatitis C virus RNA (HCV-RNA) in blood donors. Revista da Sociedade Brasileira de Medicina Tropical, 47(1), 12-17.

Makuria AT, Raghuraman S, Burbelo PD, Cantilena CC, Allison RD, Gibble J, Rehermann B, Alter HJ. The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling. Transfusion. 2012 Sep;52(9):1940-8. doi: 10.1111/j.1537-2995.2011.03524.x. Epub 2012 Feb 5. PMID: 22304422; PMCID: PMC3346857.

Zhang K, Wang L, Lin G, Li J: Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental Testing? Intervirology 2015;58:310-317. doi: 10.1159/000441474

Rafik M, Bakr S, Soliman D et al. Characterization of differential antibody production against hepatitis C virus in different HCV infection status. Virol J 13, 116 (2016).




How to Cite

Ismailova, C., Yontcheva, V., Tenev, T., & Golkocheva-Markova, E. (2021). CORRELATION BETWEEN THE ANTIBODY RESPONSE TOWARD SPECIFIC HCV PROTEINS AND HCV VIRAL LOAD. PROBLEMS of Infectious and Parasitic Diseases, 49(1), 13–18. Retrieved from




Most read articles by the same author(s)